Search

Your search keyword '"Blaakær, Jan"' showing total 666 results
Start Over Author "Blaakær, Jan"
666 results on '"Blaakær, Jan"'

5. Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer:A multicenter randomized clinical trial protocol (FRAGINOC)

Author

Daviu Cobián, Cristina, Oreskov, Jakob O., Blaakaer, Jan, Jespersen, Eva, Jørgensen, Trine L., Ryg, Jesper, Herrstedt, Jørn, Høgdall, Claus, Lund, Cecilia M., Seibæk, Lene, Vinther, Anders, Ekmann-Gade, Anne Weng, Schnack, Tine H., Daviu Cobián, Cristina, Oreskov, Jakob O., Blaakaer, Jan, Jespersen, Eva, Jørgensen, Trine L., Ryg, Jesper, Herrstedt, Jørn, Høgdall, Claus, Lund, Cecilia M., Seibæk, Lene, Vinther, Anders, Ekmann-Gade, Anne Weng, and Schnack, Tine H.

Abstract

Introduction: Radical surgery combined with chemotherapy is the only potential curative treatment of patients with advanced epithelial ovarian cancer (EOC). However, 43% of older Danish patients with EOC are not referred to surgery due to frailty, age, or fear of complications. Comprehensive geriatric assessment (CGA) has demonstrated ability to reduce frailty in older patients, but there is a knowledge gap regarding its effect before or during treatment in older adults with EOC. This protocol presents a randomized controlled trial (RCT), which evaluates the effect of CGA-based interventions including individualized physical exercise therapy in older adults with EOC during neoadjuvant chemotherapy (NACT). Materials and Methods: This RCT will include patients aged ≥70 years with primary EOC referred to NACT. Patients will be randomized 1:1 to intervention or standard of care, along with neoadjuvant antineoplastic treatment. Stratification for performance status and center of inclusion will be performed. In the intervention arm, a geriatrician will perform CGA and corresponding geriatric interventions and patients will undergo an individualized home-based exercise program managed by a physiotherapist. All patients will be evaluated with Geriatric-8, modified Geriatric-8, clinical frailty scale, and physical tests at randomization. Predictive values (positive/negative) will be evaluated for CGA detected impairments. The primary endpoint is the proportion of patients referred to interval debulking surgery (IDS). Secondary endpoints include the proportion who complete oncological treatment, improvements in physical tests, quality of life measured by European Organization for Research and Treatment of Cancer-Quality of Life questionnaires at inclusion, after three cycles of chemotherapy, and at end of chemotherapy treatment. Furthermore, the association between results of geriatric screening tests, CGA, and physical tests with complication rate and progression free sur

Published
2024

6. Circulating cell-free HPV DNA is a strong marker for disease severity in cervical cancer

Author

Bønløkke, Sara, Steiniche, Torben, Sorensen, Boe Sandahl, Nyvang, Gitte-Bettina, Lindegaard, Jacob Christian, Blaakær, Jan, Bertelsen, Jesper, Fuglsang, Katrine, Strube, Mikael Lenz, Lenz, Suzan, Stougaard, Magnus, Bønløkke, Sara, Steiniche, Torben, Sorensen, Boe Sandahl, Nyvang, Gitte-Bettina, Lindegaard, Jacob Christian, Blaakær, Jan, Bertelsen, Jesper, Fuglsang, Katrine, Strube, Mikael Lenz, Lenz, Suzan, and Stougaard, Magnus

Abstract

For cervical cancer (CC), circulating cell-free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load and survival. In this study, pre-treatment plasma from 139 CC cases (50 primary surgery patients, 22 primary surgery+adjuvant oncological therapy patients, and 67 primary oncological therapy patients) was collected (2018-2020). Furthermore, plasma from 25 cervical intraepithelial neoplasia grade 3 (CIN3) patients and 15 healthy women (negative controls) were collected. Two next-generation sequencing (NGS) panels were used to establish ccfHPV presence and human papillomavirus type 16 (HPV16) integration status. ccfHPV was detected in four primary surgery (8.0%), eight primary surgery+adjuvant oncology (36.4%), and 54 primary oncology (80.6%) patients. For primary oncology patients with HPV16-related cancer (n=37), more ccfHPVneg than ccfHPVpos patients had HPV16 integration (p=0.04), and, in patients with HPV16 integration (n=13), ccfHPVpos patients had higher disease stages than ccfHPVneg patients (p=0.05). In summary, ccfHPV presence is related to disease severity and may add to the debated Sedlis criteria used for identifying patients for adjuvant oncological therapy. However, ccfHPV detection is influenced by HPV integration status and disease stage, and these factors need to be considered in ccfHPVneg patients.

Published
2024

12. Morbidity following robot‐assisted surgery in a gynecological oncology setting: A cohort study.

Author

Markauskas, Algirdas, Blaakær, Jan, Traen, Koen Josef, Neumann, Gudrun Astrid, Chunsen, Wu, and Petersen, Lone Kjeld

Subjects
*GYNECOLOGIC surgery, *SURGICAL robots, *SURGICAL blood loss, *SURGICAL complications, *GYNECOLOGIC care, *ONCOLOGY
Abstract

Introduction: The objective of the study was to provide a comprehensive description of perioperative morbidity associated with robot‐assisted surgery (RAS) in a gynecological oncology setting in order to improve the preoperative counseling of women and support shared decision‐making. Material and Methods: All women scheduled for intended RAS between January 2015 and December 2022 were prospectively included in an electronic morbidity database for the analyses of perioperative complications. Results: In total, 2225 women were included. Sixty‐four patients (2.9%) experienced an intraoperative complication. Intraoperative complications were associated with a higher rate of conversion to laparotomy (15.6% vs. 1.8%, p < 0.001), a higher rate of major postoperative morbidity (9.3% vs. 2.4%, p < 0.001), and a higher rate of reoperation (9.3% vs. 1.7%, p < 0.001), compared to cases without intraoperative complications. Thirty‐day postoperative morbidity was evaluated according to the Memorial Sloan‐Kettering Cancer Center Surgical Secondary Events Grading System. Grade 3–5 events were considered major. A total of 57 patients (2.6%) experienced a major event after surgery, postoperative rupture of the vaginal vault being the most common complication requiring surgical intervention. Conversion to laparotomy occurred in 49 cases (2.2%) and was associated with higher intraoperative blood loss (300 mL vs. 25 mL, p < 0.001), a higher rate of postoperative major events (20.4% vs. 2.2%, p < 0.001), and a higher rate of reoperation (11.8% vs. 1.6%, p < 0.001). Conclusions: Our study demonstrates low rates of major perioperative morbidity and conversion to laparotomy after RAS performed by trained high‐volume surgeons in a gynecological oncology setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study

Author

Song, Honglin, Ramus, Susan J, Kjaer, Susanne Krüger, DiCioccio, Richard A, Chenevix-Trench, Georgia, Pearce, Celeste Leigh, Hogdall, Estrid, Whittemore, Alice S, McGuire, Valerie, Hogdall, Claus, Blaakaer, Jan, Wu, Anna H, Van Den Berg, David J, Stram, Daniel O, Menon, Usha, Gentry-Maharaj, Aleksandra, Jacobs, Ian J, Webb, Penny M, Beesley, Jonathan, Chen, Xiaoqing, Rossing, Mary Anne, Doherty, Jennifer A, Chang-Claude, Jenny, Wang-Gohrke, Shan, Goodman, Marc T, Lurie, Galina, Thompson, Pamela J, Carney, Michael E, Ness, Roberta B, Moysich, Kirsten, Goode, Ellen L, Vierkant, Robert A, Cunningham, Julie M, Anderson, Stephanie, Schildkraut, Joellen M, Berchuck, Andrew, Iversen, Edwin S, Moorman, Patricia G, Garcia-Closas, Montserrat, Chanock, Stephen, Lissowska, Jolanta, Brinton, Louise, Anton-Culver, Hoda, Ziogas, Argyrios, Brewster, Wendy R, Ponder, Bruce AJ, Easton, Douglas F, Gayther, Simon A, and Pharoah, Paul DP

Subjects
Biological Sciences, Genetics, Prevention, Human Genome, Ovarian Cancer, Clinical Research, Cancer, Breast Cancer, Aging, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Breast Neoplasms, Case-Control Studies, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Glycoproteins, Humans, Neuropeptides, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Risk Factors, White People, Australian Cancer (Ovarian) Study, Australian Ovarian Cancer Study Group, Ovarian Cancer Association Consortium, Medical and Health Sciences, Genetics & Heredity
Abstract

Because both ovarian and breast cancer are hormone-related and are known to have some predisposition genes in common, we evaluated 11 of the most significant hits (six with confirmed associations with breast cancer) from the breast cancer genome-wide association study for association with invasive ovarian cancer. Eleven SNPs were initially genotyped in 2927 invasive ovarian cancer cases and 4143 controls from six ovarian cancer case-control studies. Genotype frequencies in cases and controls were compared using a likelihood ratio test in a logistic regression model stratified by study. Initially, three SNPs (rs2107425 in MRPL23, rs7313833 in PTHLH, rs3803662 in TNRC9) were weakly associated with ovarian cancer risk and one SNP (rs4954956 in NXPH2) was associated with serous ovarian cancer in non-Hispanic white subjects (P-trend < 0.1). These four SNPs were then genotyped in an additional 4060 cases and 6308 controls from eight independent studies. Only rs4954956 was significantly associated with ovarian cancer risk both in the replication study and in combined analyses. This association was stronger for the serous histological subtype [per minor allele odds ratio (OR) 1.07 95% CI 1.01-1.13, P-trend = 0.02 for all types of ovarian cancer and OR 1.14 95% CI 1.07-1.22, P-trend = 0.00017 for serous ovarian cancer]. In conclusion, we found that rs4954956 was associated with increased ovarian cancer risk, particularly for serous ovarian cancer. However, none of the six confirmed breast cancer susceptibility variants we tested was associated with ovarian cancer risk. Further work will be needed to identify the causal variant associated with rs4954956 or elucidate its function.

Published
2009

21. Value of a catch-up HPV test in women aged 65 and above:A Danish population-based nonrandomized intervention study

Author

Tranberg, Mette, Petersen, Lone Kjeld, Hammer, Anne, Elfström, Miriam, Blaakær, Jan, Jørgensen, Susanne Fogh, Bennetsen, Mary Holten, Jensen, Jørgen Skov, and Andersen, Berit

Abstract

BACKGROUND: High-risk human papillomavirus (HPV) test is replacing cytology as the primary cervical cancer screening test due to superior sensitivity, but in most countries women ≥65 years have never had an HPV test despite they account for around 50% of cervical cancer deaths. We explored the effect of a catch-up HPV test among 65- to 69-year-old women without previous record of HPV-based screening. METHODS AND FINDINGS: This population-based nonrandomized intervention study (quasi-experimental design) included Danish women aged 65 to 69 with no record of cervical cancer screening in the last ≥5.5 years and no HPV-exit test at age 60 to 64 at the time of study inclusion. Eligible women residing in the Central Denmark Region were invited for HPV screening either by attending clinician-based sampling or requesting a vaginal self-sampling kit (intervention group, n = 11,192). Women residing in the remaining four Danish regions received standard care which was the opportunity to have a cervical cytology collected for whatever reason (reference group, n = 33,387). Main outcome measures were detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+) per 1,000 women eligible for the screening offer and the benefit-harm ratio of the intervention and standard practice measured as the number of colposcopies needed to detect one CIN2+ case. The minimum follow-up time was 13 months for all tested women (range: 13 to 25 months). In the intervention group, 6,965 (62.2%) were screened within 12 months from the date of study inclusion and 743 (2.2%) women had a cervical cytology collected in the reference group. The CIN2+ detection was significantly higher in the intervention group (3.9, 95% confidence interval (CI): [2.9, 5.3]; p < 0.001; n = 44/11,192) as compared to the reference group (0.3, 95% CI: [0.2, 0.6]; n = 11/33,387). For the benefit-harm ratio, 11.6 (95% CI: [8.5, 15.8]; p = 0.69; n = 511/44) colposcopies were performed to detect one CIN2+ in the intervention group as compared to 10.1 (95% CI: [5.4, 18.8]; n = 111/11) colposcopies in the reference group. The study design entails a risk of confounding due to the lack of randomization. CONCLUSIONS: The higher CIN2+ detection per 1,000 eligible women in the intervention group supports that a catch-up HPV test could potentially improve cervical cancer prevention in older women. This study informs the current scientific debate as to whether women aged 65 and above should be offered a catch-up HPV test if they never had an HPV test. TRIAL REGISTRATION: ClinicalTrials.gov NCT04114968.

Published
2023
Full Text
View/download PDF

28. Data from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 3 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 1 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 2 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 4 from Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer

Author

Schildkraut, Joellen M., primary, Goode, Ellen L., primary, Clyde, Merlise A., primary, Iversen, Edwin S., primary, Moorman, Patricia G., primary, Berchuck, Andrew, primary, Marks, Jeffrey R., primary, Lissowska, Jolanta, primary, Brinton, Louise, primary, Peplonska, Beata, primary, Cunningham, Julie M., primary, Vierkant, Robert A., primary, Rider, David N., primary, Chenevix-Trench, Georgia, primary, Webb, Penelope M., primary, Beesley, Jonathan, primary, Chen, Xiaoqing, primary, Phelan, Catherine, primary, Sutphen, Rebecca, primary, Sellers, Thomas A., primary, Pearce, Leigh, primary, Wu, Anna H., primary, Van Den Berg, David, primary, Conti, David, primary, Elund, Christopher K., primary, Anderson, Rebecca, primary, Goodman, Marc T., primary, Lurie, Galina, primary, Carney, Michael E., primary, Thompson, Pamela J., primary, Gayther, Simon A., primary, Ramus, Susan J., primary, Jacobs, Ian, primary, Krüger Kjaer, Susanne, primary, Hogdall, Estrid, primary, Blaakaer, Jan, primary, Hogdall, Claus, primary, Easton, Douglas F., primary, Song, Honglin, primary, Pharoah, Paul D.P., primary, Whittemore, Alice S., primary, McGuire, Valerie, primary, Quaye, Lydia, primary, Anton-Culver, Hoda, primary, Ziogas, Argyrios, primary, Terry, Kathryn L., primary, Cramer, Daniel W., primary, Hankinson, Susan E., primary, Tworoger, Shelley S., primary, Calingaert, Brian, primary, Chanock, Stephen, primary, Sherman, Mark, primary, and Garcia-Closas, Montserrat, primary

Published
2023
Full Text
View/download PDF

50. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients

Author

Bønløkke, Sara, primary, Stougaard, Magnus, additional, Sorensen, Boe Sandahl, additional, Booth, Berit Bargum, additional, Høgdall, Estrid, additional, Nyvang, Gitte-Bettina, additional, Lindegaard, Jacob Christian, additional, Blaakær, Jan, additional, Bertelsen, Jesper, additional, Fuglsang, Katrine, additional, Strube, Mikael Lenz, additional, Lenz, Suzan, additional, and Steiniche, Torben, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results